Pre-made Larcaviximab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Larcaviximab is a chimeric (mouse/human) monoclonal antibody that can be potentially used in the treatment of Ebola Virus Infection.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-297-1mg	1mg	3090
GMP-Bios-ab-297-10mg	10mg	Inquiry
GMP-Bios-ab-297-100mg	100mg	Inquiry
GMP-Bios-ab-297-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody
INN Name	Larcaviximab
Target	Zaire Ebolavirus GP
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	5ken:CD:GH:NO
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases
Conditions Approved	na
Conditions Active	Ebola virus infections
Conditions Discontinued	na
Development Tech	Zmapp Technology